Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Clinical trial NCT03199885 · TERMINATED

Trial details

NCT number: NCT03199885
Sponsor: National Cancer Institute (NCI)
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Metastatic Breast Adenocarcinoma Metastatic HER2-Positive Breast Carcinoma Recurrent Breast Adenocarcinoma Recurrent HER2-Positive Breast Carcinoma Stage III Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7 Unresectable Breast Carcinoma Unresectable HER2-Positive Breast Carcinoma

Start date: 2019-04-05
Primary completion: 2024-04-30
Enrollment: 190

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.